Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 10, 2026

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in June:

GlobeNewsWire • May 29, 2026

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with average therapy duration rising to three years and further upside from a new consumer awareness campaign. KPL-387, a next-generation IL-1 antibody, is set for phase 2 proof-of-concept data in H2 2026, offering improved economics and patient convenience compared to Arcalyst.

Seeking Alpha • Apr 29, 2026

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period. More is to come, apparently, as management raised its net sales guidance for the drug.

The Motley Fool • Apr 28, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Seeking Alpha • Apr 28, 2026

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end – – Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today –

GlobeNewsWire • Apr 28, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.

Zacks Investment Research • Apr 28, 2026

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.

GlobeNewsWire • Apr 23, 2026

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga • Apr 21, 2026

What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge

The chief accounting officer of Kiniksa Pharmaceuticals sold 6,625 shares for roughly $309,000 on April 9, 2026. The director reported still holding 27,418 Class A ordinary shares after the transaction.

The Motley Fool • Apr 17, 2026